Atrion Corporation (NASDAQ: ATRI) Stock Competitors & Peer Comparison
See ATRI's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ATRI and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ATRI | $459.92 | +0.06% | 809.4M | 64.50 | $7.13 | +1.91% |
| BDX | $156.36 | +2.22% | 56.6B | 11.62 | $13.45 | +2.39% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.39% |
| MDLN | $38.75 | +2.98% | 32.8B | 45.06 | $0.86 | N/A |
| WST | $328.20 | -7.67% | 23.2B | 41.19 | $7.97 | +0.26% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| COO | $70.31 | +0.11% | 13.7B | 15.42 | $4.56 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.39% |
| BAX | $22.40 | +3.37% | 11.6B | 10.77 | $2.08 | +0.89% |
| ATR | $132.36 | +2.61% | 8.4B | 23.13 | $5.72 | +1.43% |
Stock Comparison
Becton, Dickinson and Company (NYSE: BDX)
ATRI vs BDX Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, BDX has a market cap of 56.6B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while BDX trades at $156.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas BDX's P/E ratio is 11.62. In terms of profitability, ATRI's ROE is +0.08%, compared to BDX's ROE of +0.05%. Regarding short-term risk, ATRI is less volatile compared to BDX. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
ATRI vs BDXA Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas BDXA's P/E ratio is 45.70. In terms of profitability, ATRI's ROE is +0.08%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, ATRI is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
ATRI vs MDLN Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, MDLN has a market cap of 32.8B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while MDLN trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas MDLN's P/E ratio is 45.06. In terms of profitability, ATRI's ROE is +0.08%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, ATRI is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
ATRI vs WST Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, WST has a market cap of 23.2B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while WST trades at $328.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas WST's P/E ratio is 41.19. In terms of profitability, ATRI's ROE is +0.08%, compared to WST's ROE of +0.19%. Regarding short-term risk, ATRI is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
ATRI vs HOLX Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas HOLX's P/E ratio is 31.54. In terms of profitability, ATRI's ROE is +0.08%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, ATRI is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for ATRI.Check HOLX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
ATRI vs COO Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, COO has a market cap of 13.7B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while COO trades at $70.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas COO's P/E ratio is 15.42. In terms of profitability, ATRI's ROE is +0.08%, compared to COO's ROE of +0.03%. Regarding short-term risk, ATRI is less volatile compared to COO. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check COO's competition here
Becton, Dickinson and Company (NYSE: BDXB)
ATRI vs BDXB Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas BDXB's P/E ratio is 7.60. In terms of profitability, ATRI's ROE is +0.08%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, ATRI is less volatile compared to BDXB. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
ATRI vs BAX Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, BAX has a market cap of 11.6B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while BAX trades at $22.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas BAX's P/E ratio is 10.77. In terms of profitability, ATRI's ROE is +0.08%, compared to BAX's ROE of -0.16%. Regarding short-term risk, ATRI is less volatile compared to BAX. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check BAX's competition here
AptarGroup, Inc. (NYSE: ATR)
ATRI vs ATR Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while ATR trades at $132.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas ATR's P/E ratio is 23.13. In terms of profitability, ATRI's ROE is +0.08%, compared to ATR's ROE of +0.14%. Regarding short-term risk, ATRI is less volatile compared to ATR. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check ATR's competition here
Avantor, Inc. (NYSE: AVTR)
ATRI vs AVTR Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, AVTR has a market cap of 7.8B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while AVTR trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas AVTR's P/E ratio is 13.46. In terms of profitability, ATRI's ROE is +0.08%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, ATRI is less volatile compared to AVTR. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
ATRI vs RGEN Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, RGEN has a market cap of 7.4B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while RGEN trades at $131.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas RGEN's P/E ratio is 73.31. In terms of profitability, ATRI's ROE is +0.08%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, ATRI is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check RGEN's competition here
Teleflex Incorporated (NYSE: TFX)
ATRI vs TFX Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while TFX trades at $132.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas TFX's P/E ratio is 12.32. In terms of profitability, ATRI's ROE is +0.08%, compared to TFX's ROE of -0.28%. Regarding short-term risk, ATRI is less volatile compared to TFX. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check TFX's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
ATRI vs BLCO Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, BLCO has a market cap of 5.8B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while BLCO trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas BLCO's P/E ratio is 24.88. In terms of profitability, ATRI's ROE is +0.08%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, ATRI is less volatile compared to BLCO. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
ATRI vs STVN Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, STVN has a market cap of 5.4B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while STVN trades at $19.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas STVN's P/E ratio is 31.81. In terms of profitability, ATRI's ROE is +0.08%, compared to STVN's ROE of +0.10%. Regarding short-term risk, ATRI is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
ATRI vs MMSI Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, MMSI has a market cap of 4.4B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while MMSI trades at $74.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas MMSI's P/E ratio is 19.01. In terms of profitability, ATRI's ROE is +0.08%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, ATRI is less volatile compared to MMSI. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
ATRI vs ICUI Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while ICUI trades at $157.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas ICUI's P/E ratio is 19.66. In terms of profitability, ATRI's ROE is +0.08%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, ATRI is less volatile compared to ICUI. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check ICUI's competition here
Haemonetics Corporation (NYSE: HAE)
ATRI vs HAE Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, HAE has a market cap of 3.6B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while HAE trades at $78.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas HAE's P/E ratio is 15.86. In terms of profitability, ATRI's ROE is +0.08%, compared to HAE's ROE of +0.11%. Regarding short-term risk, ATRI is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check HAE's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
ATRI vs XRAY Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, XRAY has a market cap of 2.6B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while XRAY trades at $12.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas XRAY's P/E ratio is 9.04. In terms of profitability, ATRI's ROE is +0.08%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, ATRI is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
ATRI vs LMAT Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, LMAT has a market cap of 2.2B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while LMAT trades at $95.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas LMAT's P/E ratio is 37.05. In terms of profitability, ATRI's ROE is +0.08%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, ATRI is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check LMAT's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
ATRI vs PLSE Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, PLSE has a market cap of 2.1B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while PLSE trades at $30.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas PLSE's P/E ratio is -27.48. In terms of profitability, ATRI's ROE is +0.08%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, ATRI is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
ATRI vs ATRC Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, ATRC has a market cap of 1.8B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while ATRC trades at $35.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas ATRC's P/E ratio is 1088.20. In terms of profitability, ATRI's ROE is +0.08%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, ATRI is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
ATRI vs BLFS Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, BLFS has a market cap of 1.5B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while BLFS trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas BLFS's P/E ratio is -141.85. In terms of profitability, ATRI's ROE is +0.08%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, ATRI is less volatile compared to BLFS. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
ATRI vs AZTA Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while AZTA trades at $27.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas AZTA's P/E ratio is 60.82. In terms of profitability, ATRI's ROE is +0.08%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, ATRI is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
ATRI vs KMTS Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, KMTS has a market cap of 1.2B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while KMTS trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas KMTS's P/E ratio is -8.92. In terms of profitability, ATRI's ROE is +0.08%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, ATRI is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
ATRI vs STAA Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while STAA trades at $23.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas STAA's P/E ratio is 41.02. In terms of profitability, ATRI's ROE is +0.08%, compared to STAA's ROE of -0.06%. Regarding short-term risk, ATRI is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
ATRI vs QDEL Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, QDEL has a market cap of 1.1B. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while QDEL trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas QDEL's P/E ratio is 11.98. In terms of profitability, ATRI's ROE is +0.08%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, ATRI is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check QDEL's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
ATRI vs ANGO Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, ANGO has a market cap of 561.7M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while ANGO trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas ANGO's P/E ratio is -34.85. In terms of profitability, ATRI's ROE is +0.08%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, ATRI is less volatile compared to ANGO. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
ATRI vs NNNN Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, NNNN has a market cap of 441.5M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while NNNN trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas NNNN's P/E ratio is 145.38. In terms of profitability, ATRI's ROE is +0.08%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, ATRI is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
ATRI vs OSUR Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, OSUR has a market cap of 273.3M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while OSUR trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas OSUR's P/E ratio is -4.78. In terms of profitability, ATRI's ROE is +0.08%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, ATRI is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check OSUR's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
ATRI vs SMTI Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, SMTI has a market cap of 234.2M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while SMTI trades at $25.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas SMTI's P/E ratio is -426.00. In terms of profitability, ATRI's ROE is +0.08%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, ATRI is less volatile compared to SMTI. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check SMTI's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
ATRI vs UTMD Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, UTMD has a market cap of 213.8M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while UTMD trades at $67.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas UTMD's P/E ratio is 19.86. In terms of profitability, ATRI's ROE is +0.08%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, ATRI is less volatile compared to UTMD. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check UTMD's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
ATRI vs INFU Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, INFU has a market cap of 183.9M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while INFU trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas INFU's P/E ratio is 23.97. In terms of profitability, ATRI's ROE is +0.08%, compared to INFU's ROE of +0.14%. Regarding short-term risk, ATRI is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check INFU's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
ATRI vs KRMD Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, KRMD has a market cap of 175.9M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while KRMD trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas KRMD's P/E ratio is -95.75. In terms of profitability, ATRI's ROE is +0.08%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, ATRI is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check KRMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
ATRI vs PDEX Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, PDEX has a market cap of 175.4M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while PDEX trades at $54.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas PDEX's P/E ratio is 19.34. In terms of profitability, ATRI's ROE is +0.08%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, ATRI is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check PDEX's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
ATRI vs MBOT Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, MBOT has a market cap of 77.9M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while MBOT trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas MBOT's P/E ratio is -6.58. In terms of profitability, ATRI's ROE is +0.08%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, ATRI is less volatile compared to MBOT. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
ATRI vs AKYA Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas AKYA's P/E ratio is -1.34. In terms of profitability, ATRI's ROE is +0.08%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, ATRI is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for ATRI.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
ATRI vs STSS Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, STSS has a market cap of 58.4M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while STSS trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas STSS's P/E ratio is -0.02. In terms of profitability, ATRI's ROE is +0.08%, compared to STSS's ROE of -1.66%. Regarding short-term risk, ATRI is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check STSS's competition here
Daxor Corporation (NASDAQ: DXR)
ATRI vs DXR Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, DXR has a market cap of 52.7M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while DXR trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas DXR's P/E ratio is 27.33. In terms of profitability, ATRI's ROE is +0.08%, compared to DXR's ROE of +0.22%. Regarding short-term risk, ATRI is less volatile compared to DXR. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check DXR's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
ATRI vs OMIC Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas OMIC's P/E ratio is -0.58. In terms of profitability, ATRI's ROE is +0.08%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, ATRI is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for ATRI.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
ATRI vs IGAP Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas IGAP's P/E ratio is -10.52. In terms of profitability, ATRI's ROE is +0.08%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, ATRI is less volatile compared to IGAP. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
ATRI vs NEPH Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, NEPH has a market cap of 38.6M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while NEPH trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas NEPH's P/E ratio is 50.86. In terms of profitability, ATRI's ROE is +0.08%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, ATRI is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check NEPH's competition here
Milestone Scientific Inc. (AMEX: MLSS)
ATRI vs MLSS Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, MLSS has a market cap of 34.5M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while MLSS trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas MLSS's P/E ratio is -6.50. In terms of profitability, ATRI's ROE is +0.08%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, ATRI is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check MLSS's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
ATRI vs POCI Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, POCI has a market cap of 33.8M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while POCI trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas POCI's P/E ratio is -6.07. In terms of profitability, ATRI's ROE is +0.08%, compared to POCI's ROE of -0.37%. Regarding short-term risk, ATRI is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check POCI's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
ATRI vs SDC Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas SDC's P/E ratio is -0.03. In terms of profitability, ATRI's ROE is +0.08%, compared to SDC's ROE of -1.96%. Regarding short-term risk, ATRI is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check SDC's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
ATRI vs HBIO Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, HBIO has a market cap of 27.3M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while HBIO trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas HBIO's P/E ratio is -16.81. In terms of profitability, ATRI's ROE is +0.08%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, ATRI is less volatile compared to HBIO. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check HBIO's competition here
Invacare Corporation (NYSE: IVC)
ATRI vs IVC Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas IVC's P/E ratio is -0.79. In terms of profitability, ATRI's ROE is +0.08%, compared to IVC's ROE of -0.46%. Regarding short-term risk, ATRI is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
ATRI vs RVP Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas RVP's P/E ratio is -2.06. In terms of profitability, ATRI's ROE is +0.08%, compared to RVP's ROE of -0.08%. Regarding short-term risk, ATRI is less volatile compared to RVP. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check RVP's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
ATRI vs ZJYL Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, ZJYL has a market cap of 16M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while ZJYL trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas ZJYL's P/E ratio is 12.75. In terms of profitability, ATRI's ROE is +0.08%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, ATRI is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check ZJYL's competition here
Femasys Inc. (NASDAQ: FEMY)
ATRI vs FEMY Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, FEMY has a market cap of 11.2M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while FEMY trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas FEMY's P/E ratio is -10.25. In terms of profitability, ATRI's ROE is +0.08%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, ATRI is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check FEMY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
ATRI vs RGNT Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, RGNT has a market cap of 7.8M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while RGNT trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas RGNT's P/E ratio is -0.08. In terms of profitability, ATRI's ROE is +0.08%, compared to RGNT's ROE of N/A. Regarding short-term risk, ATRI is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check RGNT's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
ATRI vs NSTG Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas NSTG's P/E ratio is -0.03. In terms of profitability, ATRI's ROE is +0.08%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, ATRI is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check NSTG's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
ATRI vs NXGL Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, NXGL has a market cap of 4M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while NXGL trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas NXGL's P/E ratio is -1.13. In terms of profitability, ATRI's ROE is +0.08%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, ATRI is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check NXGL's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
ATRI vs POAI Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas POAI's P/E ratio is -0.03. In terms of profitability, ATRI's ROE is +0.08%, compared to POAI's ROE of -107.05%. Regarding short-term risk, ATRI is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check POAI's competition here
Lucyd, Inc (NASDAQ: LUCY)
ATRI vs LUCY Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, LUCY has a market cap of 2.6M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while LUCY trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas LUCY's P/E ratio is -0.39. In terms of profitability, ATRI's ROE is +0.08%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, ATRI is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check LUCY's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
ATRI vs MHUA Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas MHUA's P/E ratio is 0.25. In terms of profitability, ATRI's ROE is +0.08%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, ATRI is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for ATRI.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
ATRI vs NXGLW Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, NXGLW has a market cap of 1.8M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas NXGLW's P/E ratio is -0.06. In terms of profitability, ATRI's ROE is +0.08%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, ATRI is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for ATRI.Check NXGLW's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
ATRI vs GMVD Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas GMVD's P/E ratio is -0.01. In terms of profitability, ATRI's ROE is +0.08%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, ATRI is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
ATRI vs GMVDW Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas GMVDW's P/E ratio is N/A. In terms of profitability, ATRI's ROE is +0.08%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, ATRI is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
ATRI vs AVGR Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas AVGR's P/E ratio is -0.05. In terms of profitability, ATRI's ROE is +0.08%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, ATRI is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check AVGR's competition here
Lucyd, Inc (NASDAQ: LUCYW)
ATRI vs LUCYW Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas LUCYW's P/E ratio is -0.00. In terms of profitability, ATRI's ROE is +0.08%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, ATRI is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check LUCYW's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
ATRI vs GCTK Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, GCTK has a market cap of 165.2K. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while GCTK trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas GCTK's P/E ratio is -0.01. In terms of profitability, ATRI's ROE is +0.08%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, ATRI is less volatile compared to GCTK. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check GCTK's competition here
IntriCon Corporation (NASDAQ: IIN)
ATRI vs IIN Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, IIN has a market cap of 0. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas IIN's P/E ratio is 226.45. In terms of profitability, ATRI's ROE is +0.08%, compared to IIN's ROE of -0.00%. Regarding short-term risk, ATRI is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for ATRI.Check IIN's competition here
Apria, Inc. (NASDAQ: APR)
ATRI vs APR Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, APR has a market cap of 0. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas APR's P/E ratio is 22.59. In terms of profitability, ATRI's ROE is +0.08%, compared to APR's ROE of +9.81%. Regarding short-term risk, ATRI is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for ATRI.Check APR's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
ATRI vs ATRS Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas ATRS's P/E ratio is 14.95. In terms of profitability, ATRI's ROE is +0.08%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, ATRI is less volatile compared to ATRS. This indicates lower risk in terms of short-term price fluctuations for ATRI.Check ATRS's competition here
Invuity, Inc. (NASDAQ: IVTY)
ATRI vs IVTY Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas IVTY's P/E ratio is -3.80. In terms of profitability, ATRI's ROE is +0.08%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, ATRI is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for ATRI.Check IVTY's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
ATRI vs HRC Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, HRC has a market cap of 0. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas HRC's P/E ratio is 41.92. In terms of profitability, ATRI's ROE is +0.08%, compared to HRC's ROE of +0.14%. Regarding short-term risk, ATRI is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for ATRI.Check HRC's competition here
Analogic Corporation (NASDAQ: ALOG)
ATRI vs ALOG Comparison July 2026
Atrion Corporation (NASDAQ: ATRI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATRI stands at 809.4M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, ATRI is priced at $459.92 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATRI currently has a P/E ratio of 64.50, whereas ALOG's P/E ratio is 40.93. In terms of profitability, ATRI's ROE is +0.08%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, ATRI is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for ATRI.Check ALOG's competition here